Pathio District

Pathios Therapeutics Appoints Jeanmarie Guenot, Ph.D., as Non-Executive Director

Retrieved on: 
Wednesday, November 30, 2022
Pathio District, Maverick, London Bioscience Innovation Centre, Harpoon, Therapy, Patient, Myelodysplastic syndrome, Lead, Acute leukemia, GPR65, Cancer, Research, Takeda, Drug discovery, Pharmaceutical industry, Amphisbaena

OXFORD, United Kingdom, Nov. 30, 2022 /PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), a biotech company focused on developing first-in-class therapies for cancer, today announced that Jeanmarie Guenot, Ph.D., has been appointed as a non-executive director to the company's board of directors.

Key Points: 
  • OXFORD, United Kingdom, Nov. 30, 2022 /PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), a biotech company focused on developing first-in-class therapies for cancer, today announced that Jeanmarie Guenot, Ph.D., has been appointed as a non-executive director to the company's board of directors.
  • Dr. Guenot is currently the Founder, President and Chief Executive Officer of Toreador Therapeutics, a preclinical stage company discovering and developing bispecific antibody therapeutics for the treatment of cancer.
  • In 2013, she founded Amphivena Therapeutics and served as the company's President and Chief Executive Officer through the end of 2019.
  • "We are delighted to welcome Jeanmarie to Pathios to help us to deliver on the promise of targeting GPR65 as a critical innate immune checkpoint in solid tumours," said Stuart Hughes, Ph.D., Chief Executive Officer of Pathios Therapeutics.

Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022

Retrieved on: 
Thursday, November 3, 2022
TAM, Society, London Bioscience Innovation Centre, Immunotherapy, Drug discovery, Growth, GPR65, Immunosuppression, Cancer, SITC, Pathio District, Environment, Pharmaceutical industry, Vaccine, Macrophage, Mouse, Neoplasm

OXFORD, UK, Nov. 3, 2022 /PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced that new preclinical data highlighting the therapeutic potential of the company's novel GPR65 inhibition platform will be the focus of a poster presentation at the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022). Presented results will showcase the company's unique approach to "macrophage conditioning" with novel GPR65 inhibitors as a means to reversing the immunosuppression that results from an acidic tumor microenvironment, and, in turn, driving anti-tumor activity. SITC 2022 is being held November 8-12, 2022, in Boston, Massachusetts.

Key Points: 
  • SITC 2022 is being held November 8-12, 2022, in Boston, Massachusetts.
  • Launched in 2017, Pathios is a drug discovery and development company focused on translating innovative science into new medicines.
  • The company is focused on developing small-molecule inhibitors of the pH-sensing G protein-coupled receptor GPR65 to target immunosuppressive macrophages in advanced cancers.
  • Pathios is headquartered at the Innovation Centre on Milton Park, a key science precinct south of Oxford, UK.

Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022

Retrieved on: 
Tuesday, April 12, 2022
ICER, Cell, Cancer, Therapy, TAM, London Bioscience Innovation Centre, Gene expression, Immunosuppression, GPR65, Genetics, Pathio District, Tumor microenvironment, AACR, Research, Camp, American Association, Environment, Neoplasm, Association, American Association for Cancer Research, Macrophage, Drug discovery, CD8, Phenotype, NKT, Collection, Pharmaceutical industry, Vaccine

OXFORD, United Kingdom, April 12, 2022 /PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced that new data on PTT-3213, the company's orally bioavailable, potent and selective GPR65 inhibitor, were reported in a podium presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022. Presented findings from human genetic and ex vivo human cellular studies demonstrated that GPR65, a pH-sensing, G protein-coupled receptor, serves as a critical innate immune checkpoint in the human tumor microenvironment. Furthermore, data showed that inhibition of GPR65 with PTT-3213 resulted in significantly reduced tumor growth in the MC38 mouse syngeneic cancer model. The AACR conference is being held April 8-13, 2022 in New Orleans, Louisiana.

Key Points: 
  • Presented findings from human genetic and ex vivo human cellular studies demonstrated that GPR65, a pH-sensing, G protein-coupled receptor, serves as a critical innate immune checkpoint in the human tumor microenvironment.
  • Furthermore, data showed that inhibition of GPR65 with PTT-3213 resulted in significantly reduced tumor growth in the MC38 mouse syngeneic cancer model.
  • Stuart Hughes, Ph.D., Pathios' chief executive officer, delivered the podium presentation as part of the conference's "Cancer Biology and Tumor Immunity" mini-symposium.
  • Pathios' small molecule GPR65 inhibitors are able to fully counteract this polarization and re-establish an anti-tumorigenic phenotype.